Five Un-Easy Pieces of Pharmaceutical Policy Reform
Marc A. Rodwin
Suffolk University Law School; Harvard University - Edmond J. Safra Center for Ethics
Journal of Law, Medicine and Ethics, Vol. 41, p. 581, 2013
Suffolk University Law School Research Paper No. 13-24
Improper dependencies slant policy over a drug’s life span, biasing the development of new drugs, the testing and marketing approval for new drugs, and the monitoring of patient safety after drugs are marketed. This article examines five ways in which the public improperly depend on pharmaceutical firms that compromises the integrity of pharmaceutical policy. Today the public relies on pharmaceutical firms: (1) to set priorities on drug research and development; (2) to conduct clinical trials to test whether drugs are safe and effective; (3) to decide what clinical trial data to disclose to the public; (4) to monitor post marketing drug safety; (5) to supply product information to physicians and to finance continuing medical education and other professional activities. The article suggests options to overcome each of these dependencies.
Number of Pages in PDF File: 10
Date posted: July 18, 2013 ; Last revised: May 24, 2014
© 2015 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo7 in 0.250 seconds